8-K

==============================================================================

                                UNITED STATES
                     SECURITIES AND EXCHANGE COMMISSION
                           Washington, D.C. 20549

                     ----------------------------------

                                  FORM 8-K


                               CURRENT REPORT


                     PURSUANT TO SECTION 13 OR 15(d) OF
                     THE SECURITIES EXCHANGE ACT OF 1934


                        Commission File Number 1-9601


    Date of Report (date of earliest event reported): September 12, 2006


                         K-V PHARMACEUTICAL COMPANY
           (Exact name of registrant as specified in its charter)


              DELAWARE                                  43-0618919
   (State or other jurisdiction of         (I.R.S. Employer Identification No.)
   incorporation or organization)

        2503 SOUTH HANLEY ROAD
         ST. LOUIS, MISSOURI                               63144
 (Address of principal executive offices)                (Zip Code)



                               (314) 645-6600
            (Registrant's telephone number, including area code)

         Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:

  / / Written communications pursuant to Rule 425 under the Securities Act.
  / / Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  / / Pre-commencement communications pursuant to Rule 14d-2(b)
      under the Exchange Act.
  / / Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act.

==============================================================================







                          SECTION 7 - REGULATION FD

ITEM 7.01         REGULATION FD DISCLOSURE

                  Attached and incorporated herein by reference as Exhibit
99 is a press release issued by K-V Pharmaceutical Company (the "Company")
announcing that it has received notification of approval from the United
States Food and Drug Administration to market six dosages of a product. The
information in this Form 8-K, including Exhibit 99 attached hereto, is being
furnished under Regulation FD and shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended. The
Company has posted this Form 8-K on its internet website at
www.kvpharmaceutical.com. A copy of the press release is attached hereto as
Exhibit 99.

                                    * * *

                                     -2-







                                 SIGNATURES


                  Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.


Dated:  September 12, 2006

                                K-V PHARMACEUTICAL COMPANY


                                By:  /s/ Richard H. Chibnall
                                   -------------------------
                                     Richard H. Chibnall
                                     Vice President, Finance



                                     -3-

EX-99

                                                                    EXHIBIT 99

KV PHARMACEUTICAL COMPANY

                                            CONTACT:
                                            CATHERINE M. BIFFIGNANI
                                            VICE PRESIDENT, INVESTOR RELATIONS
                                            314-645-6600
                                            [KV PHARMACEUTICAL logo]




FOR IMMEDIATE RELEASE

       KV PHARMACEUTICAL COMPANY RECEIVES ANDA APPROVAL FROM U.S. FDA
               FOR SIX STRENGTHS OF DILTIAZEM HCl ER CAPSULES


  6-MONTH EXCLUSIVITY ON 420MG DILTIAZEM STRENGTH; FIRST COMPANY WITH FULL
          LINE OF DOSAGE STRENGTHS WHICH ARE AB RATED TO TIAZAC(R)

St. Louis, MO, September 12, 2006 - KV Pharmaceutical Company (NYSE:
KVa/KVb) announced today that it has received approval from the U.S. Food
and Drug Administration to market six strengths of Diltiazem HCl ER Capsules
(AB rated to Tiazac(R) from Forest Pharmaceuticals, Inc.) through its
wholly-owned generic/non-branded subsidiary, ETHEX Corporation. ETHEX will
begin shipments of all six strengths immediately.

The launch of the six strengths of Diltiazem (120mg, 180mg, 240mg, 300mg,
360mg and 420mg) will complement ETHEX's highly regarded cardiovascular
family of products and will make KV the first generic company that will have
a full line of product AB-rated to Tiazac(R). KV also believes it is the
first generic company to receive approval of the 420mg strength dosage, and
thus expects to have six months exclusivity on this strength. However, it is
also expected that the brand manufacturer may launch an "authorized generic"
version. Total market sales for this product are approximately $160 million.
Tiazac(R) is indicated for the treatment of hypertension (high blood
pressure) and angina (chest pain).

Tiazac(R) belongs to a class of drugs known as calcium channel blockers
(CCBs) that lower blood pressure by blocking calcium influx into the smooth
muscle cells of the blood vessels. CCBs may be used to treat high blood
pressure, angina and some arrhythmias. Approximately 50 million people in
the U.S. have hypertension, however, approximately 52% are not on therapy
and only 21% are on adequate control which controls their hypertension.
Hypertension is a lifelong condition and can remain asymptomatic for many
years. It is very important to reach one's blood pressure goal and maintain
that goal throughout one's life.

Marc S. Hermelin, Chairman of the Board and Chief Executive Officer stated,
"We are delighted to be extending ETHEX's cardiovascular expertise into the
CCB segment with a complete line of AB-rated equivalents to an outstanding
product like Tiazac(R). The approval extends ETHEX's





line-up of quality ANDA products across multiple therapeutic categories,
with several more important opportunities in our pipeline. We are pleased to
be able to offer a full line of this important product to our customers and
patients."

ABOUT KV PHARMACEUTICAL COMPANY
KV Pharmaceutical Company is a fully integrated specialty pharmaceutical
company that develops, manufactures and markets and acquires
technology-distinguished branded and generic/non-branded prescription
pharmaceutical products. The Company markets its technology distinguished
products through ETHEX Corporation, a national leader in pharmaceuticals
that compete with branded products, and Ther-Rx Corporation, its emerging
branded drug subsidiary. KV has consistently ranked as one of America's
fastest growing small companies, most recently by Forbes in its November
2004 issue.

For further information about KV Pharmaceutical Company, please visit the
Company's corporate website at www.kvpharmaceutical.com.

SAFE HARBOR
- -----------
The information in this release may contain various forward-looking
statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include
assumptions concerning KV's operations, future results and prospects. Such
statements may be identified by the use of words like "plans", "expect",
"aim", "believe", "projects", "anticipate", "commit", "intend", "estimate",
"will", "should", "could" and other expressions that indicate future events
and trends.

All statements that address expectations or projections about the future,
including without limitation, statements about the Company's strategy for
growth, product development, regulatory approvals, market position,
acquisitions, revenues, expenditures and other financial results, are
forward-looking statements.

All forward-looking statements are based on current expectations and are
subject to risk and uncertainties. In connection with the "safe harbor"
provisions, KV provides the following cautionary statements identifying
important economic, political and technology factors which, among others,
could cause actual results or events to differ materially from those set
forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) changes in
the current and future business environment, including interest rates and
capital and consumer spending; (2) the difficulty of predicting FDA
approvals, including timing, and that any period of exclusivity may not be
realized; (3) acceptance and demand for new pharmaceutical products; (4) the
impact of competitive products and pricing, including as a result of
so-called authorized-generic drugs; (5) new product development and launch,
including the possibility that any product launch may be delayed or that
product acceptance may be less than anticipated; (6) reliance on key
strategic alliances; (7) the availability of raw materials; (8) the
regulatory environment, including regulatory agency and judicial actions and
changes in applicable law or regulations; (9)






fluctuations in operating results; (10) the difficulty of predicting
international regulatory approval, including timing; (11) the difficulty of
predicting the pattern of inventory movements by the Company's customers;
(12) the impact of competitive response to the Company's sales, marketing
and strategic efforts; (13) risks that the Company may not ultimately
prevail in litigation; and (14) the risks detailed from time to time in the
Company's filings with the Securities and Exchange Commission.

This discussion is by no means exhaustive, but is designed to highlight
important factors that may impact the Company's outlook. We are under no
obligation to update any of the forward-looking statements after the date of
this report.